AgomAb Therapeutics NV competitors & alternatives

ChemomabBiotechIsrael

70% match

Similar biotech company

Chemomab is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. Based in Tel Aviv, Israel, the company builds its treatments on unique scientific insights.

Mestag TherapeuticsBiotechnologyUnited Kingdom

70% match

Biotechnology

Mestag Therapeutics is an immunotherapy company focusing on fibroblast-immune biology to address critical unmet needs in inflammatory diseases and oncology. The company operates across hubs including Cambridge, United Kingdom, and Ghent, Belgium.

Similar biotech company

Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.

Biotechnology

Mediar Therapeutics is a clinical-stage biotechnology company that develops novel antibody therapies to halt and reverse fibrotic diseases. The company focuses on deactivating myofibroblasts to treat conditions such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and kidney fibrosis.

FNC BiotechBiotechnology

68% match

Biotechnology

FNC Biotech is a biotechnology company established in 2021 that focuses on the development of antibody therapeutics for idiopathic pulmonary fibrosis and cancer.

Alentis TherapeuticsBiotechnologySwitzerland

68% match

Biotechnology

Alentis Therapeutics is a Swiss biotechnology company developing antibody-based medicines that target Claudin-1 (CLDN1), a protein involved in tumor biology and tissue fibrosis. Its therapies are intended for patients with solid tumors and fibrotic diseases, including liver and other organ fibrosis.

ARGENX NV ARGENX0QW0 · BiotechUnited Kingdom

68% matchPublicAI 7/100Green 5/100

Similar biotech company

Argenx NV is a global immunology company that researches, develops, and commercializes antibody-based therapies for patients suffering from severe autoimmune diseases. The company's proprietary product portfolio includes treatments such as VYVGART and VYVGART Hytrulo, which are designed to target and address pathogenic antibodies.

Ocean Biomedical, Inc.OCEA · BiotechProvidence, United States

68% matchPublic

Similar biotech company

Ocean Biomedical, Inc. operates as a biopharmaceutical firm committed to identifying and advancing novel therapeutic solutions for various medical challenges, including cancer, fibrotic disorders, infectious illnesses, and inflammation. The company's pipeline includes the development of both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are specifically designed to target Chi3l1, offering potential treatments for non-small cell lung cancer and glioblastoma multiforme. Additionally, they are progressing a small molecule drug candidate aimed at Chit1, intended to address Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Leveraging its proprietary WPDS platform, Ocean Biomedical is also developing three further product candidates. These encompass a promising malaria vaccine, a humanized mAb therapeutic for malaria that targets the Plasmodium falciparum glutamic-acid-rich protein (PfGARP), and a small molecule malaria therapeutic also designed to interact with PfGARP. Furthermore, a treatment candidate for hospitalized COVID-19 patients is also under development. The company, established in 2019, maintains its operations in Providence, Rhode Island.

Biotechnology

aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.

Similar biotech company

InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.

Similar biotech company

Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.

Pliant Therapeutics, Inc.PLRX · BiotechnologySouth San Francisco, United States

67% matchPublic

Biotechnology

Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.